CompletedPhase 2NCT01767194
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
Studying Ganglioneuroblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Rajen Mody, MB BSChildren's Oncology Group
- Intervention
- Dinutuximab(biological)
- Enrollment
- 73 enrolled
- Eligibility
- All sexes
- Timeline
- 2013 – 2022
Study locations (30)
- Phoenix Childrens Hospital, Phoenix, Arizona, United States
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Kaiser Permanente Downey Medical Center, Downey, California, United States
- Loma Linda University Medical Center, Loma Linda, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Valley Children's Hospital, Madera, California, United States
- Kaiser Permanente-Oakland, Oakland, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
- Sutter Medical Center Sacramento, Sacramento, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- Rady Children's Hospital - San Diego, San Diego, California, United States
- UCSF Medical Center-Parnassus, San Francisco, California, United States
- UCSF Medical Center-Mission Bay, San Francisco, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
United Therapeutics
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01767194 on ClinicalTrials.govOther trials for Ganglioneuroblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07502287Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory NeuroblastomaBeijing Biotech
- RECRUITINGPHASE3NCT07375563Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and GanglioneuroblastomaFederal Research Institute of Pediatric Hematology, Oncology and Immunology
- RECRUITINGPHASE3NCT06172296Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk NeuroblastomaNational Cancer Institute (NCI)
- RECRUITINGNANCT05192980SIOPEN BIOPORTAL, An International Registry Linked to a Virtual Biobank for Patients With Peripheral Neuroblastic TumoursInstitut Curie
- RECRUITINGNCT06296732Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors StratificationFederal Research Institute of Pediatric Hematology, Oncology and Immunology
- RECRUITINGPHASE3NCT06071897Induction Chemoimmunotherapy for Patients With High-risk NeuroblastomaFederal Research Institute of Pediatric Hematology, Oncology and Immunology
- ACTIVE NOT RECRUITINGPHASE2NCT04385277Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)Children's Oncology Group
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT04040088An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine TumorsMayo Clinic